Chlamydia vaccine shows early promise in mice

An experimental vaccine has shown promise in protecting against the sexually transmitted disease chlamydia, researchers report.

Lab mice given the vaccine were able to rapidly clear subsequent chlamydia infections, and were less likely to develop severe infections compared with unvaccinated mice, researchers reported Nov. 11 in the journal npj Vaccines.

The vaccine contains chlamydia whole-cell bacteria that have been killed using radiation, the study authors added.

Although killed by radiation, the bacteria prompt an immune response because they’ve been protected by a powerful antioxidant, the study explained. The antioxidant keeps the surface proteins needed to produce an immune response intact, while killing off the bacteria itself.

The antioxidant protection created a whole-cell chlamydia vaccine that increased antibody levels more than 16-fold in mice.

On the other hand, vaccines made without the antioxidant produced low levels of antibodies.

“All of these findings just make sense to me,” said lead researcher George Liechti, a professor with the Uniformed Services University of the Health Sciences’ Department of Microbiology and Immunology in Bethesda, Md. “If you want an effective whole-cell chlamydia vaccine, then you should probably try not to cook, zap or otherwise damage the surface antigens that it relies on.”

More than 1.6 million chlamydia infections occurred in 2022, researchers said in background notes. Most of the reported cases occurred in young women ages 15 to 24.